Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.15
-$0.76-1.81%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 30.76% | -- | -- | 363.82% | 2,858.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.76% | -- | -- | 363.82% | 2,858.58% |
| Cost of Revenue | 39.25% | 14.39% | 23.91% | 2.00% | 30.12% |
| Gross Profit | -237.62% | 2.76% | -343.52% | 14.85% | 94.42% |
| SG&A Expenses | 193.89% | 152.83% | 95.40% | 89.98% | 116.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.54% | 86.88% | 60.09% | 36.85% | 69.49% |
| Operating Income | -195.13% | -78.71% | -528.27% | -27.82% | -4.24% |
| Income Before Tax | -208.13% | -73.87% | -447.17% | -15.72% | 8.10% |
| Income Tax Expenses | -- | -- | -- | -- | -100.00% |
| Earnings from Continuing Operations | -208.13% | -73.91% | -447.17% | -15.72% | 8.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -208.13% | -73.91% | -447.17% | -15.72% | 8.43% |
| EBIT | -195.13% | -78.71% | -528.27% | -27.82% | -4.24% |
| EBITDA | -194.75% | -78.38% | -535.99% | -27.56% | -3.85% |
| EPS Basic | -157.60% | -51.42% | -396.53% | 10.39% | 29.06% |
| Normalized Basic EPS | -142.18% | -51.01% | -432.08% | 8.72% | 26.64% |
| EPS Diluted | -157.60% | -51.42% | -388.25% | 10.20% | 29.46% |
| Normalized Diluted EPS | -142.18% | -51.01% | -432.08% | 8.72% | 26.64% |
| Average Basic Shares Outstanding | 19.60% | 14.85% | 10.21% | 29.12% | 29.15% |
| Average Diluted Shares Outstanding | 19.60% | 14.85% | 10.21% | 29.12% | 29.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |